• Bulletin of the Korean Chemical Society
• /
• 제20권4호
• /
• pp.389-391
• /
• 1999

• 대한화학회지
• /
• 제16권1호
• /
• pp.33-39
• /
• 1972

The stabilization energies by interconjugations at the transition states in various Diels-Alder reactions were calculated. It has been found that the stabilization energies are inversely proportional to resonance energies of isolated molecules of polyene and heterocyclic system before reactions. It has been noted that the resonance energies of dienes are smaller than those of dienophiles in two different molecules. Therefore, the possibility of charge-transfer from dienes to dienophiles is hinted.

• 대한화학회지
• /
• 제40권10호
• /
• pp.670-673
• /
• 1996

• Journal of Applied Biological Chemistry
• /
• 제49권2호
• /
• pp.62-64
• /
• 2006

• Bulletin of the Korean Chemical Society
• /
• 제11권4호
• /
• pp.258-260
• /
• 1990

• 대한화학회지
• /
• 제23권5호
• /
• pp.286-295
• /
• 1979

非對稱으로 置環된 diene과 dienophile 間의 反應에서 配向性에 미치는 산촉매의 효과를 豫期하기 위해서 루이스酸과 錯物을 形成한 dienophile의 理論的모델에 FMO 理論을 적용하여CNDO/2 방법으로 고찰하였다. 電子的性質이 類似한 치환기로 치환된 diene, dienophile의 반응(즉, 電子不足 diene과 電子不足 dienophile의 반응)에서 일어나는 半極性 고리化반응을 제외한 주어진 대부분의 반응에 대해서, CNDO/2방법이 실험적인 配向性과 一致하는 좋은 결과를 주었다. 또한 二次軌道相互作用이 非對稱으로 치환된 diene과 dienophile의 Diels-Alder 반응의 배향성에 중요한 역할을 했다는 사실을 보여주었다. Anh의 방법이 다른 방법보다 수식적으로 간단할지라도, 非對稱전이상태를 강조한 Anh의 방법이 配向性 결정에 좋은 결과를 주었다.

• Journal of Applied Biological Chemistry
• /
• 제48권2호
• /
• pp.97-100
• /
• 2005

Chiral dienophile 5 was synthesized from D-glucose by consecutive diisopropylidenation, partial deprotection, diol cleavage, and Wittig reactions. Under thermal conditions, asymmetric Diels-Alder reaction between chiral dienophile and cyclopentadiene gave four possible chiral norbornenes stereoisomers whose absolute configurations were determined through CADD and NMR.

• 대한화학회지
• /
• 제40권7호
• /
• pp.483-491
• /
• 1996

Cyclopentadiene과 exo-cyclic 이중결합을 가진 5각고리 화합물간의 Diels-Alder반응을 PM3 방법을 이용하여 연구하였다. Dienophile의 종류가 바뀌어도 전이상태의 구조는 커다란 변화를 나타내지 않았다. 반면에 dienophile의 exocyclic C(=O)-R 결합의 회w전에 의하여 나타나는 두 conformer들은 서로 다른 생성물을 얻을 수 있었으며, 이들의 반응성을 FMO들의 energy gap을 이용하여 설명하였다. 반면에 dienophile의 접근방향에 따른 exo, endo경로의 선택성을 살펴보기 위하여 전이상태에서의 deformation enerhy와 활성와 에너지간의 상관관계를 살펴보았다. 반응의 최저 에너지 경로를 Curtin-Hammett principle을 사용하여 논의 하였다.

• 한국자기공명학회논문지
• /
• 제8권1호
• /
• pp.62-69
• /
• 2004

Bicyclolactones obtained from the Diels-Alder cycloaddition of 3,5-dibromo-2-pyrone can undergo various palladium catalyzed cross coupling reactions to afford aryl bicyclolactones. The resulting coupled products can be readily converted into various 3-OH cyclohexenes via lactone ring openings, while those bearing dienyl units underwent highly diastereoselective Diels-Alder cycloadditions with selected dienophiles to funish multiply functionalized polycarbocycles. Bromo-bicyclic diene furnished two different diastereomers endo-form (62%) and exo-form (38%) upon cycloadditions with N-Et maleimide (NEM), and their stereochemistries were identified with NMR.

• 대한방사성의약품학회지
• /
• 제6권1호
• /
• pp.53-58
• /
• 2020

Pretargeting is a two-component strategy often used for tumor targeting to enhance the tumor-to-background ratio in cancer diagnosis as well as therapy. In the multistep strategy, the highly specific unlabeled monoclonal antibodies (mAbs) with the reactive site is allowed to get localized at tumor site first, and then small and fastclearing radiolabeled chelator with counter reactive site is administered which covalently attaches to mAbs via inverse electron demand Diels-Alder reaction (IEDDA). The catalyst-free IEDDA cycloaddition reaction between 1,2,4,5-tetrazines and strained alkene dienophiles aid with properties like selective bioconjugation, swift and high yielding bioorthogonal reactions are emergent in the development of radiopharmaceutical. Due to its fast pharmacokinetics, the in vivo formed radioimmunoconjugates can be imaged at earlier time points by short-lived radionuclides like ¹⁸F and ⁶⁸Ga; it can also reduce radiation damage to the normal cells. Ultimately, this review elucidates the updated status of pretargeting based on antibodies and IEDDA for tumor diagnosis (PET and SPECT) and therapy.